Loading…
Neumora Therapeutics, Inc. is projected to decline to $1.59 by 2027, a -5% move from its current price of $1.68. NMRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.57 | $1.68 | $1.79 | -0.16% |
| Jul 14 | $1.53 | $1.67 | $1.84 | -0.32% |
| Jul 15 | $1.49 | $1.67 | $1.87 | -0.47% |
| Jul 16 | $1.47 | $1.67 | $1.90 | -0.63% |
| Jul 17 | $1.44 | $1.67 | $1.93 | -0.79% |
| Jul 18 | $1.42 | $1.66 | $1.95 | -0.94% |
| Jul 19 | $1.40 | $1.66 | $1.97 | -1.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.40 | $1.66 | $1.97 | -1.10% |
| Week 2 | $1.29 | $1.64 | $2.10 | -2.19% |
| Week 3 | $1.21 | $1.63 | $2.19 | -3.26% |
| Week 4 | $1.14 | $1.61 | $2.27 | -4.32% |
| Week 5 | $1.08 | $1.59 | $2.34 | -5.38% |
| Week 6 | $1.03 | $1.57 | $2.40 | -6.42% |
| Week 7 | $0.9848 | $1.55 | $2.46 | -7.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics, Inc. (NMRA) trades at $1.59 per share and has a market cap of $294.6M, ranking 3527 by market capitalization.
The current price and market position place NMRA in a small-cap tier with notable volatility. The technical picture shows a broad range in the near term, with a 30-day range spanning $1.01 to $2.50, reflecting a dynamic trading environment. The forecast landscape projects a multi-year upside, with an average price rising into the low/high teens by 2050 under the max scenario, though projections include substantial variability and are not guaranteed.
A major floor 68.7% below — a decisive break under it would weaken the trend.
The nearest floor, 45.5% below — buyers have tended to step in here.
The nearest ceiling, 11.9% above — a clean break opens room to run.
A major ceiling 100.9% above — clearing it would confirm fresh momentum.
Key NMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.67 | Buy | $1.66 | Buy |
| MA 10 | $1.67 | Buy | $1.65 | Buy |
| MA 20 | $1.59 | Buy | $1.65 | Buy |
| MA 50 | $1.78 | Sell | $1.79 | Sell |
| MA 100 | $2.22 | Sell | $1.97 | Sell |
| MA 200 | $2.19 | Sell | $2.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.40 | Neutral |
| Stoch RSI (14) | 80.81 | Sell |
| CCI (20) | 50.22 | Neutral |
| Williams %R (14) | -18.52 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 4.35 | Buy |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 81.48 | Sell |
| TRIX (15) | -0.40 | Sell |
| Awesome (5,34) | 0.00 | Buy |
| Ultimate (7,14,28) | 50.79 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 1.65 | Buy |
| ADX (14) | 9.87 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is NEUTRAL overall. RSI14 is 50, indicating a balanced short-term momentum.
The stock is trading below its SMA50 of $1.80 and SMA200 of $2.19, which can imply limited near-term upside unless momentum shifts. Support sits at $0.915 and resistance at $1.88, framing a near-term trading band. The 30-day range runs from $1.01 to $2.50, highlighting a defined but broad short-term trading corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.915 | $1.68 | $1.96 | 0% | Neutral | |
| $1.16 | $1.59 | $2.37 | -5% | Neutral | |
| $1.25 | $1.83 | $2.91 | +9% | Neutral | |
| $1.38 | $2.13 | $3.54 | +27% | Bullish | |
| $1.57 | $2.54 | $4.41 | +51% | Bullish | |
| $1.50 | $2.54 | $4.56 | +51% | Bullish | |
| $1.32 | $2.33 | $4.31 | +39% | Bullish | |
| $1.17 | $2.15 | $4.09 | +28% | Bullish | |
| $1.16 | $2.22 | $4.34 | +32% | Bullish | |
| $1.58 | $3.14 | $6.26 | +87% | Bullish | |
| $1.51 | $3.37 | $7.39 | +100% | Bullish | |
| $3.16 | $7.02 | $16.15 | +318% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.915 | $1.68 | $2.08 | +0.00% |
| August 2026 | $1.33 | $1.61 | $2.04 | -3.94% |
| September 2026 | $1.18 | $1.45 | $1.87 | -9.86% |
| October 2026 | $1.17 | $1.46 | $1.91 | +0.12% |
| November 2026 | $1.21 | $1.52 | $2.01 | +4.04% |
| December 2026 | $1.14 | $1.45 | $1.96 | -4.18% |
Click any year to see its month-by-month NMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NMRA price prediction for 2026 points to an average of $1.68 (low $0.915, high $1.96) — a potential gain of 0% on today's $1.68. A consolidation phase looks the most probable path here.
In 2027, NMRA is projected to trade between $1.16 and $2.37, averaging $1.59 — a potential decline of -5% from today's $1.68. That is -5% versus the projected 2026 average. Price action looks broadly range-bound.
Neumora Therapeutics, Inc.'s 2028 outlook centres on $1.83, within a $1.25 to $2.91 range. That is up +15% on the projected 2027 average. That marks a +9% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, NMRA could reach as high as $3.54, with a base case around $2.13 and support toward $1.38 — roughly +27% from $1.68. Momentum favours further upside here.
Expect NMRA to range from $1.57 to $4.41 through 2030. The $2.54 average target implies a +51% move from current prices. That is up +20% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The NMRA price prediction for 2031 points to an average of $2.54 (low $1.50, high $4.56) — a potential gain of +51% on today's $1.68. Momentum favours further upside here.
In 2032, NMRA is projected to trade between $1.32 and $4.31, averaging $2.33 — a potential gain of +39% from today's $1.68. That is -8% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Neumora Therapeutics, Inc.'s 2033 outlook centres on $2.15, within a $1.17 to $4.09 range. That is -8% versus the projected 2032 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2034, NMRA could reach as high as $4.34, with a base case around $2.22 and support toward $1.16 — roughly +32% from $1.68. Buyers look set to stay in control over this stretch.
Expect NMRA to range from $1.58 to $6.26 through 2035. The $3.14 average target implies a +87% move from current prices. That is up +41% on the projected 2034 average. Momentum favours further upside here.
The NMRA price prediction for 2040 points to an average of $3.37 (low $1.51, high $7.39) — a potential gain of +100% on today's $1.68. Buyers look set to stay in control over this stretch.
In 2050, NMRA is projected to trade between $3.16 and $16.15, averaging $7.02 — a potential gain of +318% from today's $1.68. That is up +109% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NMRA today (≈ 595.238095 NMRA) could be worth
$4,178.78
+$3,178.78 (+318%) by 2050 · US Dollar
Based on the average projected NMRA price of $7.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NMRAwould be worth at today's price.
$1,000 invested in NMRA on Jul 10, 2025 (≈ 943.396277 NMRA) would be worth
$1,584.91
+$584.91 (+58.5%) today · 1.58× · US Dollar
Based on a NMRA entry price of $1.06 vs. today's $1.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.67 | $1,005.99 | +0.6% |
| 1 month ago | $1.6 | $1,050 | +5.0% |
| 3 months ago | $2.04 | $823.53 | -17.6% |
| 6 months ago | $2.22 | $756.76 | -24.3% |
| 1 year ago | $1.06 | $1,584.91 | +58.5% |
| All time (2.8y) ago | $17 | $98.82 | -90.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NMRA forecast.
Our base-case forecast reaches $3.40 around 2050.
Implied market cap at $3.40: $629.97M
The multi-year forecast shows a bullish trajectory beginning in 2030. The 2030 average price is $2.29 with a min of $1.42 and a max of $3.98, and the ROI is 44.3%. By 2040 the average rises to $2.86 with an ROI of 79.9% (min $1.29, max $6.28) and the sentiment remains BULLISH.
By 2050 the average is $5.93 with an ROI of 272.9% (min $2.67, max $13.64), continuing the bullish outlook.
Notable intermediate years include 2035 with an average of $2.64 and ROI of 66.2%, supporting a generally upward trajectory into the late decade. These figures illustrate meaningful upside under the max scenario, but they are estimates and not guarantees; volatility and market conditions can lead to deviations from the projections.
Tap a question to reveal the answer.
2030 average price is $2.29 with a min of $1.42, a max of $3.98 and an ROI of 44.3%; sentiment is BULLISH.
The long-term forecast shows a bullish trajectory beginning in 2030 with averages rising to $2.29 (2030), $2.86 (2040), and $5.93 (2050) with ROIs up to 272.9% by 2050. These are estimates and not guarantees.
Yes. The 2050 forecast maximum is $13.64, which exceeds $10.
Current price is $1.59 and market cap is $294.6M. The rank by market cap is 3527.
The 30-day range is from $1.01 to $2.50.
Neumora Therapeutics, Inc. Community Discussion
0Share your Neumora Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.